No Data
No Data
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics Faces Challenges in Developing Hepatitis B Treatments Amidst Industry Competition
H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Cuts Target Price to $70
Aligos Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Aligos Therapeutics Analyst Ratings
Express News | Aligos Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $70 From $75